PROFESSOR OF MEDICINE, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Oncology
Dr. Ravi Vij, MD
|
|
Give Review
Ravi Vij is an expert in the field of Oncology. He went to medical school at Rush Medical College of Rush University. Rush Medical College of Rush University has a rank of 67 in research and a 0 in primary care He has 2 awards "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Ravi has written publications. He has 75 publications published with PubMed. The lastest paper is: 'Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.' Doctor Ravi Vij, MD accepts all Medicare patients.
Publications
- Central Nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
- Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Result...
- A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.
- Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
- Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen:...
- New Approaches to Molecular Imaging of Multiple Myeloma.
- Impact of Pre-transplant Therapy and Depth of Disease Response prior to Autologous Transplantation for Multiple Myeloma.
- A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
- Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy.
- Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic Cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
- Haploidentical transplantation using G-CSF-mobilized T-Cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated wi...
- Vatalanib population pharmacokinetics in patients with myelodysplastic Syndrome (MDS): CALGB 10105 (Alliance).
- PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resi...
- A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
- Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4.
- Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
- Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhi...
- Allotransplantation for patients age 40 years and greater with non-Hodgkin Lymphoma (NHL): encouraging progression-free survival.
- Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
- Phase I study of oral clofarabine consolidation in adults aged 60 and older with Acute myeloid leukemia.
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
- Recombinant interleukin-2 in patients aged younger than 60 years with Acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808.
- Haematological Cancer: A step before the next leap?
- Effect of post remission therapy prior to reduced intensity conditioning allogeneic transplantation for Acute myeloid leukemia in first complete remission.
- Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Co...
- Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma.
- Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma.
- A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (...
- A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine inDuction in the treatment of AML.
- Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein upregulates expression of the anti-leukemic microRNA-181a in Acute myeloid leukemia.
- Trends in allogeneic stem cell transplantation for multiple myeloma: a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis.
- Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and Acute myeloid leukemia: A phase I study.
- Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
- Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin Lymphoma treated with standard salvage chemotherapy and autologous stem cell transplanta...
- Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
- Initial genome sequencing and Analysis of multiple myeloma.
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
- High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory Acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with Acute myeloid leukemia.
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed Acute myeloid leukemia: Cance...
- Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemothe...
- Molecular pathology of myeloproliferative Neoplasms.
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
- Primary plasma cell Leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004.
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.
- Salvage therapy for Acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
- A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic Syndromes.
- Arterial Thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
- Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal Acute myelo...
- Prognostic factors influencing survival in solitary plasmacytoma.
- Clofarabine: a size that fits all, may not fit all.
- Single-agent lenalidomide induces complete remission of Acute myeloid leukemia in patients with isolated trisomy 13.
- Dasatinib in relapsed or plateau-phase multiple myeloma.
- Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.
- Impact of mobilization and remobilization strategies on achieving sufficient stem Cell yields for autologous transplantation.
- Rapid mobilization of functional donor hematopoietic Cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
- Cancer- and chemotherapy-induced anemia.
- Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin Lymphoma.
- Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem Cell transplant recipients: a multicenter, randomized, double-blind, placebo-contr...
- Bortezomib inhibits osteoclast activity in patients with multiple myeloma.
- Copper deficiency: an important consideration in the differential diagnosis of myelodysplastic Syndrome.
- A randomized double-blind trial of hydroxychloroquine for the prevention of Chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
- The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma.
- Long-term remissions in patients with myelodysplastic syndrome and secondary Acute myelogenous leukemia undergoing allogeneic transplantation following a reduced inten...
- Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor Cell transplantation result in...
- Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irrad...
- Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's Lymphoma.
- Long-term outcomes of allogeneic stem Cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.
- Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a...
- Donor CMV serostatus has no impact on CMV viremia or Disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell trans...
- Recent advances in allogeneic hematopoietic stem-Cell transplantation.
- Targeted treatments for multiple myeloma: specific role of carfilzomib.
- Germinal center B-Cells resist transformation by kras independently of tumor suppressor arf.
- A CD138-independent strategy to detect minimal residual Disease and circulating tumour cells in multiple myeloma.
Schools
University of Delhi Maulana Azad Medical College
Rush Presbyn St Luke39s Med Center
Barnes Jewish Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
Washington University -
Rush Medical College of Rush University -
Maulana Azad Medical College
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1023034337 | |
| NPPES Provider LastName | VIJ | |
| NPPES Provider FirstName | RAVI | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 912.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 88.0 | |
| Percent Opioid Claims | 9.65 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1023034337 |
| Last Name Of The Provider | VIJ |
| First Name Of The Provider | RAVI |
| View All |
Similar Doctors
|
|
Dr. Antonella L. Rastelli, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vikram C. Gorantla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Pincus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John J. Dombrowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory D. Longmore, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Emily S. Popovic, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark E. Woodson, MD |
|
|
Dr. Marianna B. Ruzinova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David D. Tran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul J. Petruska, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph Prah, MD |
|
|
Dr. Ali A. Mohamed, MD |
|
|
Dr. Keith E. Stockerl-Goldstein, MD
This Doctor is OpenDoctor Recommended.
|